Samalizumab - Alexion Pharmaceuticals

Drug Profile

Samalizumab - Alexion Pharmaceuticals

Alternative Names: ALXN 6000

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion Pharmaceuticals; The Leukemia & Lymphoma Society
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD200 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma

Most Recent Events

  • 01 Sep 2017 Alexion Pharmaceuticals terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02987504)
  • 03 Aug 2017 Alexion Pharmaceuticals suspends patient enrolment in a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02987504)
  • 27 Jul 2017 Samalizumab is available for licensing as of 27 Jul 2017. http://ir.alexionpharm.com/releasedetail.cfm?ReleaseID=1034669
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top